AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02782910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-Based Ambulatory Assessment, Feedback via physician
Description: Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
Study NCT02850588 — intervention group
Intervention type: PROCEDURE
Intervention: Transcarotid artery revascularization
Description: Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
Study NCT02850588 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
Study NCT03573492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Type of teaching being assigned to student arms
Study NCT03563092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery
Description: Standardized minimally invasive approach to inguinal hernia repair
Study NCT03563092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery
Description: Standardized minimally invasive approach to inguinal hernia repair
Study NCT01344148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH RIF Rifb PZA EMB AZT 3TC D4T EFV
Description: The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
Study NCT06556316 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social Cognitive Communication Program
Description: An 11 week group intervention targeting social and cognitive-communication abilities
Study NCT06556316 — intervention group
Intervention type: DEVICE
Intervention: Non-Invasive Brain Stimulation with tDCS
Description: 20 minute tDCS intervention as a non-invasive neuromodulation treatment
Study NCT00994097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
Study NCT00994097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
Study NCT00306397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
Study NCT01641575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO-1.01 and Cisplatin
Description: CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
Study NCT04437186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery program
Description: The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
Study NCT05282329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating Current Stimulation (tACS)-active
Description: Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
Study NCT05282329 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation (tACS)-sham
Description: Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
Study NCT03400878 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Japan
Description: One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
Study NCT03794349 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dinutuximab
Description: Given IV
Study NCT03794349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV
Study NCT03794349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine Hydrochloride
Description: Given PO or via NG or G tube
Study NCT03794349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT03794349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT03794349 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Description: Given SC or IV
Study NCT03794349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC or IV
Study NCT03794349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO or via NG or G tube
Study NCT03794349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO or via NG or G tube
Study NCT00854360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate HFA Nasal Aerosol
Description: Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
Study NCT03400878 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Russia
Description: One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
Study NCT04034628 — intervention group
Intervention type: DEVICE
Intervention: Peritoneal Catheter Insertion - Laparoscopic
Description: Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
Study NCT00854360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: HFA Vehicle Aerosol
Study NCT00854360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HFA Vehicle Aerosol
Study NCT04088396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT04088396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Administered SC
Study NCT04626102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)
Description: The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session.
Study NCT04626102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)
Description: This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below.
Study NCT02025790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per Oral Endoscopic Myotomy (POEM)
Description: * Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).~* Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~* Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~* Long endoscopic myotomy is performed 10 cm proximal to GEJ extending~* Closure of mucosal entry: the mucosal incision is closed using hemostatic clips
Study NCT02025790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Dilatation
Description: Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
Study NCT04946604 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ashtangayoga
Description: This is an active and intense type of yoga, focused on physical activity and breath control
Study NCT04034628 — intervention group
Intervention type: DEVICE
Intervention: Peritoneal Catheter Insertion - Percutaneous
Description: Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
Study NCT02990689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal Intraocular Lens
Description: bifocal intraocular lens (IOL)
Study NCT02990689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bifocal Intraocular Lens
Description: trifocal intraocular lens (IOL)
Study NCT02990689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Addition Bifocal Intraocular Lens
Description: low near addition intraocular lens (IOL)
Study NCT04055974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be a Mom
Description: The Be a Mom program is a web-based self-guided cognitive-behavioral intervention targeting postpartum women. It consists of 5 weekly modules, each targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
Study NCT00477984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol
Description: alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
Study NCT02461264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single red blood packed cells Transfusion
Study NCT01501357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified toothbrush with multilevel filaments
Description: After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
Study NCT02829632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Sessions
Description: Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.
Study NCT02829632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.
Study NCT02829632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will receive an one-time how to self-monitor using the smartphone session.
Study NCT01501357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cross toothbrushing
Description: Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
Study NCT04183348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Protocol n°1 first at Visit 1, then, Training Protocol n°2 at Visit 2
Description: During Protocol 1 (visit 1), participants of Group A will perform auditory spatial localization tasks with sensory feedback and during Protocol 2 (visit 2), they will perform auditory tasks without any notion of spatial localization. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol.
Study NCT04183348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Protocol n°2 first at Visit 1, then, Training Protocol n°1 at Visit 2
Description: During Protocol 2 (visit 1), participants of Group B will perform auditory tasks without any notion of spatial localization and during Protocol 1 (visit 2), they will perform auditory spatial localization tasks with sensory feedback. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol.
Study NCT00454116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily oral tablet two doses
Study NCT00454116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Description: Intravenous infusion
Study NCT00454116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Intravenous infusion
Study NCT03186339 — intervention group
Intervention type: PROCEDURE
Intervention: TAVI
Description: transfemoral transcatheter aortic valve implantation
Study NCT03186339 — intervention group
Intervention type: PROCEDURE
Intervention: SAVR
Description: isolated surgical valve replacement
Study NCT03186339 — intervention group
Intervention type: OTHER
Intervention: MM
Description: management of aortic stenosis by medical treatment only
Study NCT02431325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Study NCT02431325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00611221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage therapy by an RMT during labour
Study NCT00611221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage by anyone else, eg. husband, nurse, doula
Study NCT05594108 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: transabdominal ultrasonography
Study NCT03077763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite
Study NCT01644942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lipid accumulation analysis
Description: The lipid accumulation will be assessed with muscular biopsies.
Study NCT02420223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study NCT00884052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose levetiracetam
Description: 20 mg/kg loading dose; 5 mg/kg daily for 7 days.
Study NCT00884052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose levetiracetam
Description: 40 mg/kg IV load; 10 mg/kg/day maintenance
Study NCT01461408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Session
Description: The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect-their hairdressers-will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.~The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26.
Study NCT04439370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microneurography to measure muscle sympathetic nerve activity (MSNA)
Description: Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves
Study NCT04439370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Baroreflex sensitivity testing
Description: Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.
Study NCT04439370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sympathoexcitatory Maneuvers
Description: Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed
Study NCT04439370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: Serum FSH, estrogen, progesterone, and testosterone will be measured
Study NCT04625894 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED > 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.
Study NCT04625894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle
Description: Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
Study NCT01028833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power mobility
Description: Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
Study NCT01262612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: immediate cediranib
Description: cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
Study NCT01262612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Start cediranib after 28 days Best Supportive Care
Description: patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
Study NCT02104999 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Point-of-care test for CRP
Description: Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
Study NCT01128569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: FF
Study NCT01128569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/Vilanterol (VI; GW642444M)
Description: FF/VI
Study NCT01128569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Inhaler
Study NCT00894387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg and Aliskiren 300 mg
Study NCT00894387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04239248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tasty&Healthy intervention group
Description: patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty\&Healthy.
Study NCT02461264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two packed red blood cells Transfusion